Business Context and Reporting Period
This Form 8-K Current Report was filed by Oscar Health, Inc. on May 29, 2026. The filing discloses a material change in executive leadership and compensation arrangements effective June 1, 2026.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive personnel changes and does not contain financial performance data.
Material Changes Versus Prior Period
The primary material change involves the transition of Mario Schlosser from President of Technology and Chief Technology Officer to Co-Founder & Advisor to the CEO. Key changes to his compensation package include:
- Base Salary: Reduced to $370,000 annually, effective June 1, 2026.
- Annual Bonus: Mr. Schlosser is no longer eligible for the annual bonus program commencing with calendar year 2026.
- Equity Awards: No new long-term incentive or equity-based awards will be granted during the term of the agreement, though previously granted awards will continue to vest.
- Severance and Benefits: Mr. Schlosser is not entitled to cash severance payments or Company-subsidized healthcare coverage upon termination.
Guidance, Outlook, and Management Commentary
Management indicates that in his new advisory role, Mr. Schlosser will focus on accelerating the Company's artificial intelligence and digital health agenda to drive innovation in consumer-driven healthcare. He will continue to serve on the Company's Board of Directors. The filing does not provide specific financial guidance, risk factors, or contingencies beyond the terms of the employment agreement.
Important Facts for Investor Verification
- Confirm the exact effective date of the role transition (June 1, 2026) and the immediate impact on the Company's technology leadership structure.
- Verify the total reduction in executive compensation costs resulting from the removal of bonus eligibility and new equity grants for Mr. Schlosser.
- Review the vesting schedules of Mr. Schlosser's previously granted equity awards to understand future dilution or expense recognition.
- Assess the strategic implications of shifting the Co-Founder to an advisory role while retaining Board membership.